choline has been researched along with lc15-0444 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SE; Han, SJ; Heo, YJ; Jeon, JY; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Lee, N | 1 |
| Do, IG; Kim, J; Kim, SH; Lee, Y; Park, CY; Song, Y; Yang, H | 1 |
2 other study(ies) available for choline and lc15-0444
| Article | Year |
|---|---|
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.
Topics: Amino Acids; Animals; Benzhydryl Compounds; Choline; Cytokines; Diet, High-Fat; Disease Models, Animal; Disease Progression; Glucosides; Inflammation; Inflammation Mediators; JNK Mitogen-Activated Protein Kinases; Liver; Macrophage Activation; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phosphorylation; Piperidones; Protective Agents; Pyrimidines | 2022 |
Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Autophagy-Related Protein-1 Homolog; Choline; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Humans; Inflammasomes; Intracellular Signaling Peptides and Proteins; Methionine; Mice; Non-alcoholic Fatty Liver Disease | 2023 |